Egrifta (Tesamorelin) for HIV

Overview
Egrifta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to reduce excess abdominal fat in adult patients living with HIV and lipodystrophy. Egrifta is also known by its drug name, Tesamorelin. Egrifta is a growth hormone-releasing factor (GHRF) analog. Egrifta is believed to work by metabolising hard belly fat.

How do I take it?
Egrifta is generally injected subcutaneously once a day. Egrifta comes as a concentrated liquid in a vial and is measured and administered with a syringe.

Side effects
The FDA-approved label for Egrifta lists common side effects including redness and itchiness at the injection site, swelling in the hands and feet, and muscle and joint pain. Rare but serious side effects listed for Egrifta include an increased risk of certain cancers, diabetes, and allergic reactions.

For more details about this treatment, visit:

Egrifta — Theratechnologies